Stock Events

Stock Events

Viatris 

$16.88
1610
-$0.06-0.35% 19:59 Today
+$0.08+0.47%21:57After hours

Statistics

Day High
17.02
Day Low
16.67
52W High
18.39
52W Low
9.43
Volume
5,599,203
Avg. Volume
9,709,133
Mkt Cap
19.39B
P/E Ratio
-
Dividend Yield
2.84%
Dividend
0.48

Upcoming

Dividends

2.84%Dividend Yield
Sep 26
$0.12
Jun 26
$0.12
Mar 26
$0.12
Dec 25
$0.12
Sep 25
$0.12
10Y Growth
N/A
5Y Growth
34.27%
3Y Growth
N/A
1Y Growth
N/A

Earnings

9NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
0.49
0.56
0.62
0.69
Expected EPS
0.650484
Actual EPS
N/A

Financials

-24.58%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
14.3BRevenue
-3.51BNet Income

Analyst Ratings

20.00Average Price Target
The highest estimate is 22.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
67%
Hold
33%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow VTRS. It's not an investment recommendation.
Pfizer
398
PFE
AT&T
325
T
Realty Income
300
O
Apple
282
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap42.46B
Teva Pharmaceutical Industries is a direct competitor, focusing on generic and specialty medicines, similar to Viatris' product offerings.
Pfizer
PFE
Mkt Cap159.36B
Pfizer, originally part of Viatris through Upjohn, competes in the pharmaceuticals space, offering both branded and generic drugs.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie competes with Viatris in the specialty pharmaceutical sector, particularly in areas like biosimilars and branded generics.
Novartis
NVS
Mkt Cap292.35B
Novartis, through its Sandoz division, is a major player in the generic drugs market, making it a direct competitor to Viatris.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson competes across a broad range of healthcare products, including pharmaceuticals that overlap with Viatris' market.
Merck
MRK
Mkt Cap366B
Merck & Co. competes with Viatris in the pharmaceutical sector, particularly in the development and marketing of prescription medicines.
GSK
GSK
Mkt Cap101.78B
GlaxoSmithKline competes in the pharmaceutical and healthcare sector, with a portfolio that includes prescription medicines and vaccines.
AMGEN
AMGN
Mkt Cap233.78B
Amgen competes with Viatris in the biopharmaceutical sector, particularly in the development of biosimilars and novel therapeutics.
Sanofi
SNY
Mkt Cap107.39B
Sanofi competes in the global pharmaceutical market, offering a broad portfolio of prescription drugs that overlaps with Viatris' offerings.

About

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
Show more...
CEO
Scott Andrew Smith
Employees
30000
Country
United States
ISIN
US92556V1061
WKN
000A2QAME

Listings

LSE
GB
0A5V.LSE
STU
DE
VIA.STU
XNAS
US
VTRS
MU
DE
VIA.MU

0 Comments

Share your thoughts

FAQ

What is Viatris stock price today?▼
The current price of VTRS is $16.88 USD — it has decreased by -0.35% in the past 24 hours. Watch Viatris stock price performance more closely on the chart.
What is Viatris stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Viatris stocks are traded under the ticker VTRS.
Is Viatris stock price growing?▼
VTRS stock has risen by +3.3% compared to the previous week, the month change is a -4.63% fall, over the last year Viatris has showed a +63.41% increase.
What is Viatris market cap?▼
Today Viatris has the market capitalization of 19.39B
When is the next Viatris earnings date?▼
Viatris is going to release the next earnings report on November 09, 2026.
What were Viatris earnings last quarter?▼
VTRS earnings for the last quarter are 0.69 USD per share, whereas the estimation was 0.6 USD resulting in a +14.79% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Viatris revenue for the last year?▼
Viatris revenue for the last year amounts to 14.3B USD.
What is Viatris net income for the last year?▼
VTRS net income for the last year is -3.51B USD.
Does Viatris pay dividends?▼
Yes, VTRS dividends are paid quarterly. The last dividend per share was 0.12 USD. As of today, Dividend Yield (FWD)% is 2.84%.
How many employees does Viatris have?▼
As of September 04, 2026, the company has 30,000 employees.
In which sector is Viatris located?▼
Viatris operates in the Health & Wellness sector.
When did Viatris complete a stock split?▼
Viatris has not had any recent stock splits.
Where is Viatris headquartered?▼
Viatris is headquartered in CANONSBURG, United States.